A vaccine production strain of Bordetella bronchiseptica that produces Bordetella pertussis toxin in high yield

Available for licensing from the NIH is a vaccine production strain of Bordetella bronchiseptica that produces Bordetella pertussis toxin in high yield. The Bordetella bronchiseptica strain has been modified to eliminate expression of filamentous hemagglutinin, which typically has to be removed in purification of the toxin, thereby reducing the yield of the active vaccine component. Immediately available for licensing is a strain that encodes a mutated pertussis toxin, which does not have to be chemically detoxified. Application: Production of Bordatella pertussis toxin for acellular vaccine use.

U.S. Patent No. 7,101,558 issued 05 Sep 2006 (HHS Reference No. E-159-1999/0-US-03) Inventors: Tod Merkel, Jerry Keith, and Xiaoming Yang (NIDCR)

Licensees sought: Available for non-exclusive licensing.